The latest from CDMOs, CMOs, and suppliers featuring Oxford Biomedical, Piramal Pharma Solutions, and Upperton Pharma Solutions.  

Biologics Manufacturing 
* Oxford Biomedical Raises $125 M in Growth Strategy 
Formulation Development/Drug Product Manufacturing 
* Piramal Pharma, NewAmsterdam Pharma Invest in Mfg Suite  
* Upperton Pharma Receives Grant for Oral Adenovirus Vector Vaccines  

---

Biologics Manufacturing 

Oxford Biomedical Raises $125 M in Growth Strategy
Oxford Biomedical (OXB), a cell and gene therapy CDMO, has announced that it has secured a new four-year loan facility of up to $125 million, provided by funds managed by Oaktree Capital Management.  

The new facility will strengthen the Company’s financial foundation by refinancing its existing $50-million loan facility and providing financial flexibility to support OXB’s global CDMO operations and the delivery of its growth strategy. 

The New Oaktree Loan facility includes $60 million upfront funding available at closing, which will be used to repay an existing $50-million four-year term loan facility with Oaktree (previously announced in October 2022) and for general corporate purposes. The facility also includes the option to draw down a further $25 million, subject to customary conditions, and an additional $40 million, subject to achieving certain revenue milestones. 

Source: Oxford Biomedical 

---

Formulation Development/Drug Product Manufacturing 

Piramal Pharma, NewAmsterdam Pharma Open Solid Dosage Suite 
Piramal Pharma Solutions, a CDMO of active pharmaceutical ingredients and drug products, and NewAmsterdam Pharma, a late-stage bio/pharmaceutical company focused on metabolic diseases, have announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal’s facility in Sellersville, Pennsylvania. The new suite will facilitate the production of NewAmsterdam Pharma’s investigational fixed-dose combination product, a non-statin cholesterol medication to reduce low-density lipoprotein cholesterol.

The Sellersville site provides development and manufacturing services for various formulations, including several forms of OSDs. The new suite represents a multi-million-dollar investment in equipment upgrades and enhancements, includes a reconfiguration of existing space to create a dedicated OSD suite that will be used exclusively for fixed-dose combination products. The new suite is designed for turnkey, multi-layer tablet production and is equipped with advanced capabilities and technology to support granulation, compression, tableting, and coating. 

Source: Piramal Pharma Solutions 

---

Upperton Pharma Receives Grant for Oral Adenovirus-Vectored Vaccines
Upperton Pharma Solutions, a UK-based CDMO, has been awarded a grant as part of the first VaxHub Sustainable Platform Funding Call, in collaboration with the University of Oxford. The funding supports the development of an oral formulation for adenovirus-vectored vaccines. 

The VaxHub Sustainable Platform Funding Call, launched in January 2025, aims to support innovative projects aligned with sustainable vaccine development. This work is supported by funding from the UK Engineering and Physical Sciences Research Council for the Manufacturing Research Hub for a Sustainable Future (VaxHub Sustainable) co-directed by University College London and the University of Oxford with UK university partners.  

The project, led by Professor Dame Sarah Gilbert at the University of Oxford’s Pandemic Sciences Institute, aims to address the limitations of intramuscular vaccine administration. By exploring oral delivery routes, the team seeks to induce mucosal immunity, improve vaccine stability, simplify distribution, and support self-administration. The joint project is expected to be completed in the summer 2026. 

Source: Upperton Pharma Solutions